

## SGLT-2 Inhibitors

	Dapagliflozin (Forxiga <sup>®</sup> )	Canagliflozin (Invokana <sup>®</sup> )	Empagliflozin (Jardiance <sup>®</sup> )▼	Ertugliflozin (Steglatro <sup>®</sup> )▼
<b>Dose</b>	10mg once daily	100mg once daily, increased to 300mg once daily if insufficient response	10mg once daily, increased to 25mg once daily if insufficient response	5mg once daily, increased to 15mg once daily if insufficient response
<b>Formulations</b>	5mg and 10mg tablets.	100mg and 300mg tablets	10mg and 25mg tablets	5mg and 15mg tablets
<b>Combination formulations:</b>	<ul style="list-style-type: none"> <li>•Qtern<sup>®</sup> (dapagliflozin 10mg/saxagliptin 5mg)</li> <li>•Xigduo<sup>®</sup> (dapagliflozin 5mg/metformin 850mg or 1g)</li> </ul>	Vokanamet <sup>®</sup> (Canagliflozin 50mg/metformin 850mg or 1g) ▼	Synjardy <sup>®</sup> (empagliflozin 5mg or 12.5mg/metformin 850mg or 1g) ▼	<ul style="list-style-type: none"> <li>•Steglujan<sup>®</sup> (ertugliflozin 5mg or 15mg/sitagliptin 100mg) ▼</li> <li>•Segluromet<sup>®</sup> (ertugliflozin 2.5mg or 7.5mg/metformin 850mg or 1g) ▼</li> </ul>
<b>Combination data:</b>	Metformin, sulfonylureas, DPP4-i's, exenatide, insulin. Not recommended with pioglitazone.	Metformin, sulfonylureas, pioglitazone, sitagliptin, insulin	Metformin, sulfonylureas, pioglitazone, DPP4-i's, insulin.	Metformin, sulfonylureas, DPP4-i's, insulin.
<b>Adjustment for elderly</b>	Initiation not recommended in patients ≥75 years old	None.	Initiation not recommended in patients ≥85 years old	None, but experience limited in patients ≥75 years old
<b>Adjustment for renal impairment</b>	Not recommended if eGFR or CrCl<60ml/min	Not recommended if eGFR or CrCl<45ml/min. Do not initiate if eGFR or CrCl<60ml/min and do not exceed 100mg daily in existing patients.	Not recommended if eGFR or CrCl<45ml/min. Do not initiate if eGFR or CrCl<60ml/min and do not exceed 10mg daily in existing patients.	Not recommended if eGFR or CrCl<45ml/min. Do not initiate if eGFR or CrCl<60ml/min.
<b>Adjustment for hepatic impairment</b>	Starting dose 5mg in severe hepatic impairment (may be increased to 10mg if tolerated).	Not recommended in severe hepatic impairment.	Not recommended in severe hepatic impairment.	Not recommended in severe hepatic impairment.
<b>NICE TAS</b>	<a href="#">TA288</a> : Dapagliflozin in combination therapy <a href="#">TA390</a> : Canagliflozin, dapagliflozin and empagliflozin as monotherapies <a href="#">TA418</a> : Dapagliflozin in triple therapy	<a href="#">TA315</a> : Canagliflozin in combination therapy <a href="#">TA390</a> : Canagliflozin, dapagliflozin and empagliflozin as monotherapies	<a href="#">TA336</a> : Empagliflozin in combination therapy <a href="#">TA390</a> : Canagliflozin, dapagliflozin and empagliflozin as monotherapies	<a href="#">TA572</a> : Ertugliflozin as monotherapy or with metformin <a href="#">TA583</a> : Ertugliflozin with metformin and a DPP4-inhibitor

This table is an extract from an evidence review of SGLT-2 Inhibitors (November 2018). For further information please contact the author (details below).

**References:**

1. Summary of Product Characteristics. Forxiga 5mg/10mg film-coated tablets (dapagliflozin). AstraZeneca UK Limited. Accessed via [www.medicines.org.uk/emc/](http://www.medicines.org.uk/emc/)
2. Summary of Product Characteristics. Invokana 100mg and 300mg film-coated tablets (canagliflozin hemihydrate). Napp Pharmaceuticals Limited. Accessed via [www.medicines.org.uk/emc/](http://www.medicines.org.uk/emc/)
3. Summary of Product Characteristics. Jardiance 10mg/25mg film-coated tablets (empagliflozin). Boehringer Ingelheim Limited. Accessed via [www.medicines.org.uk/emc/](http://www.medicines.org.uk/emc/)
4. Summary of Product Characteristics. Steglatro 5mg/15mg film-coated tablets (ertugliflozin). Merck Sharp & Dohme Limited. Accessed via [https://www.ema.europa.eu/documents/product-information/steglatro-epar-product-information\\_en.pdf](https://www.ema.europa.eu/documents/product-information/steglatro-epar-product-information_en.pdf)
5. Cinti F, Moffa S, Impronta F, et al. Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date. Drug Design, Development and Therapy 2017;11:2905-2919